Cargando…
Evaluation of a spot-on imidacloprid-moxidectin formulation (Advocate®) for the treatment of naturally occurring esophageal spirocercosis in dogs: a double-blinded, placebo-controlled study
BACKGROUND: Dogs are the definitive hosts of Spirocerca lupi. Spirocercosis is treated by prolonged avermectin administration by injection or daily oral doses. In this prospective, double-blinded, placebo-controlled, clinical trial, the efficacy of imidacloprid and moxidectin spot-on formulation (Ad...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5838953/ https://www.ncbi.nlm.nih.gov/pubmed/29506575 http://dx.doi.org/10.1186/s13071-018-2731-x |
_version_ | 1783304338968412160 |
---|---|
author | Segev, Gilad Rojas, Alicia Lavy, Eran Yaffe, Marganit Aroch, Itamar Baneth, Gad |
author_facet | Segev, Gilad Rojas, Alicia Lavy, Eran Yaffe, Marganit Aroch, Itamar Baneth, Gad |
author_sort | Segev, Gilad |
collection | PubMed |
description | BACKGROUND: Dogs are the definitive hosts of Spirocerca lupi. Spirocercosis is treated by prolonged avermectin administration by injection or daily oral doses. In this prospective, double-blinded, placebo-controlled, clinical trial, the efficacy of imidacloprid and moxidectin spot-on formulation (Advocate®) was compared to injectable doramectin (Dectomax®). Dogs diagnosed with benign esophageal spirocercosis were divided randomly into doramectin (400 μg/kg IM) or moxidectin and imidacloprid spot-on (2.5–6.25 mg/kg and 10–25 mg/kg, respectively) groups and treated weekly for 12 consecutive weeks. Dogs were followed for 20 weeks by physical examination, owners’ questionnaire, blood work, fecal floatation, PCR and endoscopy. RESULTS: All the doramectin group dogs (n = 10) completed the treatment and follow-up, and the disease had completely resolved in all by week 12. Of the Advocate® group (n = 10), four had complete resolution at week 12, four had partial resolution, one dog did not respond to treatment, and one dog was switched to the doramectin protocol on week 5 due to persistent severe clinical signs. PCR analysis was more sensitive in detecting S. lupi eggs compared to fecal floatation. Discrepancies were detected on 22 occasions, of which on 20 occasions, the PCR was positive while fecal floatation was negative, and only on two occasions the PCR results were negative while fecal flotation was positive. CONCLUSIONS: The present results indicate that weekly Advocate® spot-on administration may be effective for treating benign esophageal spirocercosis, but is less effective than the currently used injectable doramectin therapy at the dose and duration used herein. |
format | Online Article Text |
id | pubmed-5838953 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-58389532018-03-09 Evaluation of a spot-on imidacloprid-moxidectin formulation (Advocate®) for the treatment of naturally occurring esophageal spirocercosis in dogs: a double-blinded, placebo-controlled study Segev, Gilad Rojas, Alicia Lavy, Eran Yaffe, Marganit Aroch, Itamar Baneth, Gad Parasit Vectors Research BACKGROUND: Dogs are the definitive hosts of Spirocerca lupi. Spirocercosis is treated by prolonged avermectin administration by injection or daily oral doses. In this prospective, double-blinded, placebo-controlled, clinical trial, the efficacy of imidacloprid and moxidectin spot-on formulation (Advocate®) was compared to injectable doramectin (Dectomax®). Dogs diagnosed with benign esophageal spirocercosis were divided randomly into doramectin (400 μg/kg IM) or moxidectin and imidacloprid spot-on (2.5–6.25 mg/kg and 10–25 mg/kg, respectively) groups and treated weekly for 12 consecutive weeks. Dogs were followed for 20 weeks by physical examination, owners’ questionnaire, blood work, fecal floatation, PCR and endoscopy. RESULTS: All the doramectin group dogs (n = 10) completed the treatment and follow-up, and the disease had completely resolved in all by week 12. Of the Advocate® group (n = 10), four had complete resolution at week 12, four had partial resolution, one dog did not respond to treatment, and one dog was switched to the doramectin protocol on week 5 due to persistent severe clinical signs. PCR analysis was more sensitive in detecting S. lupi eggs compared to fecal floatation. Discrepancies were detected on 22 occasions, of which on 20 occasions, the PCR was positive while fecal floatation was negative, and only on two occasions the PCR results were negative while fecal flotation was positive. CONCLUSIONS: The present results indicate that weekly Advocate® spot-on administration may be effective for treating benign esophageal spirocercosis, but is less effective than the currently used injectable doramectin therapy at the dose and duration used herein. BioMed Central 2018-03-05 /pmc/articles/PMC5838953/ /pubmed/29506575 http://dx.doi.org/10.1186/s13071-018-2731-x Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Segev, Gilad Rojas, Alicia Lavy, Eran Yaffe, Marganit Aroch, Itamar Baneth, Gad Evaluation of a spot-on imidacloprid-moxidectin formulation (Advocate®) for the treatment of naturally occurring esophageal spirocercosis in dogs: a double-blinded, placebo-controlled study |
title | Evaluation of a spot-on imidacloprid-moxidectin formulation (Advocate®) for the treatment of naturally occurring esophageal spirocercosis in dogs: a double-blinded, placebo-controlled study |
title_full | Evaluation of a spot-on imidacloprid-moxidectin formulation (Advocate®) for the treatment of naturally occurring esophageal spirocercosis in dogs: a double-blinded, placebo-controlled study |
title_fullStr | Evaluation of a spot-on imidacloprid-moxidectin formulation (Advocate®) for the treatment of naturally occurring esophageal spirocercosis in dogs: a double-blinded, placebo-controlled study |
title_full_unstemmed | Evaluation of a spot-on imidacloprid-moxidectin formulation (Advocate®) for the treatment of naturally occurring esophageal spirocercosis in dogs: a double-blinded, placebo-controlled study |
title_short | Evaluation of a spot-on imidacloprid-moxidectin formulation (Advocate®) for the treatment of naturally occurring esophageal spirocercosis in dogs: a double-blinded, placebo-controlled study |
title_sort | evaluation of a spot-on imidacloprid-moxidectin formulation (advocate®) for the treatment of naturally occurring esophageal spirocercosis in dogs: a double-blinded, placebo-controlled study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5838953/ https://www.ncbi.nlm.nih.gov/pubmed/29506575 http://dx.doi.org/10.1186/s13071-018-2731-x |
work_keys_str_mv | AT segevgilad evaluationofaspotonimidaclopridmoxidectinformulationadvocateforthetreatmentofnaturallyoccurringesophagealspirocercosisindogsadoubleblindedplacebocontrolledstudy AT rojasalicia evaluationofaspotonimidaclopridmoxidectinformulationadvocateforthetreatmentofnaturallyoccurringesophagealspirocercosisindogsadoubleblindedplacebocontrolledstudy AT lavyeran evaluationofaspotonimidaclopridmoxidectinformulationadvocateforthetreatmentofnaturallyoccurringesophagealspirocercosisindogsadoubleblindedplacebocontrolledstudy AT yaffemarganit evaluationofaspotonimidaclopridmoxidectinformulationadvocateforthetreatmentofnaturallyoccurringesophagealspirocercosisindogsadoubleblindedplacebocontrolledstudy AT arochitamar evaluationofaspotonimidaclopridmoxidectinformulationadvocateforthetreatmentofnaturallyoccurringesophagealspirocercosisindogsadoubleblindedplacebocontrolledstudy AT banethgad evaluationofaspotonimidaclopridmoxidectinformulationadvocateforthetreatmentofnaturallyoccurringesophagealspirocercosisindogsadoubleblindedplacebocontrolledstudy |